Table.
HUS cases | Controls | ||||||
---|---|---|---|---|---|---|---|
Author | Year | Country | Duration of study | Study population with HUS | Positive for STEC (%) | Population | Positive for STEC (%) |
Cordovéz* (14) | 1992 | Chile | 1988-1989 | 20 | 6 (30.0) | 38 | 2 (5.3) |
Gianviti (15) | 1994 | Italy | 1988-1992 | 68 | 49 (72.0) | 58 | 2 (3.0) |
Greatorex (16) | 1994 | USA | 1989-1992 | 27 | 23 (85.2) | 47 | 3 (6.4) |
Jure (17) | 1998 | Argentina | 1994-1996 | 19 | 12 (63.2) | 17 | 0 |
Karmali (18) | 1985 | Canada | 1980-1983 | 40 | 24 (60.0) | 40 | 0 |
Kishore (19) | 1992 | India | NA | 28 | 19 (67.9) | 25 | 0 |
Kleanthous* (20) | 1990 | United Kingdom | 1985-1988 | 185 | 58 (31.3) | 148 | 9 (6.1) |
Lopez (21) | 1989 | Argentina | 1986-1988 | 51 | 34 (66.7) | 64 | 13 (20.3) |
Total | 438 | 437 | |||||
Median (IQR) | 64.95 (52.8-68.9) | 4.15 (0-6.175) |
*No serology tests;
HUS=Haemolytic-uraemic
syndrome;
IQR=Interquartile range;
NA=Not applicable;
STEC=Shiga toxin-producing Escherichia coli